In this issue:
Ibrutinib–rituximab or chemoimmunotherapy for CLL
Cost effectiveness of CAR T-cell therapy in DLBCL
Nivolumab for newly diagnosed Hodgkin lymphoma
Clofarabine can replace anthracyclines + etoposide in childhood AML
Anti-KIR3DL2 mAb IPH4102 in cutaneous T-cell lymphoma
Treatment value of secondgeneration BCR-ABL1 TKIs
Ibrutinib + fludarabine, cyclophosphamide, and rituximab in CLL
Obinutuzumab + lenalidomide for follicular B-cell lymphoma
Brentuximab + AVD for Hodgkin’s lymphoma
Idarubicin, etoposide + sequential or concurrent azacitidine for AML
Please login below to download this issue (PDF)